Enterprise Value

8.203B

Cash

362.1M

Avg Qtr Burn

-18.34M

Short % of Float

12.63%

Insider Ownership

5.78%

Institutional Own.

78.24%

Qtr Updated

12/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
VK2809 (THR-B agonist) Details
Non-alcoholic steatohepatitis

Big Mover™

Susp. Mover™

Phase 2b

Data readout

Phase 2

Update

Phase 1b

Data readout

VK2735 (Oral formulation) (GLP-1R & GIPR agonist) Details
Metabolic disorder

Big Mover™

Susp. Mover™

Phase 1

Data readout

VK5211 (SARM) Details
Muscle injury following hip fracture

Failed

Discontinued